Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 | Q09428 | 1/20 | 0.60 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | CLK1 | P49759 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.42 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20435728 | 0.80 | ABCC8 (0.58) | ABCC8KCNJ11KDM4EMAPTALDH1A1 | |
| SCHEMBL20435729 | 0.79 | ABCC8 (0.56) | ABCC8KCNJ11KDM4EMAPTALDH1A1 | |
| SCHEMBL20435730 | 0.79 | ABCC8 (0.56) | ABCC8KCNJ11KDM4EMAPTALDH1A1 | |
| SCHEMBL2090089 | 0.76 | ABCC8 (1.00) | ABCC8KCNJ11KDM4EMAPTALDH1A1 | |
| SCHEMBL20435738 | 0.71 | ABCC8 (0.54) | ABCC8KCNJ11KDM4EMAPTALDH1A1 | |
| SCHEMBL20435731 | 0.69 | ABCC8 (0.62) | ABCC8KCNJ11KDM4EMAPTALDH1A1 | |
| SCHEMBL8268996 | 0.68 | PDE10A (0.81) | PDE10A | |
| SCHEMBL12292152 | 0.68 | ADORA2A (0.62) | KDM4EMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL20435739 | 0.67 | ABCC8 (0.42) | ABCC8KCNJ11MAPTALDH1A1CLK1 | |
| SCHEMBL25110139 | 0.67 | GRM5 (0.44) | ABCC8KCNJ11MEN1KMT2ACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | Zander Biologics, Inc (US) | 2022-07-05 | — | — | US | disclosed |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | KCL THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200071307-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS | Zander Therapeutics, Inc. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10472351-B2 | Small molecule agonists and antagonists of NR2F6 activity in animals | Zander Therapeutics, Inc. (US) | 2019-11-12 | — | — | US | disclosed |
| WO-2019104199-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY | REGEN BIOPHARMA INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019104201-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN NON-HUMANS | Zander Therapeutics, Inc. (US) | 2019-05-31 | — | — | WO | disclosed |
| US-20190054118-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals | Zander Therapeutics, Inc. | 2019-02-21 | — | — | US | disclosed |
| US-20180214413-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | KCL THERAPEUTICS, INC | 2018-08-02 | — | — | US | disclosed |
| US-20180214413-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | KCL THERAPEUTICS, INC | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214413-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | NR4A2, NR2C2, NR0B2 | ABCC8 1987/4885KCNJ11 4734/4885KDM4E 3440/4885 |
| US-20200071307-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS | NR4A2, NR2C2, NR0B2 | ABCC8 2042/4885KCNJ11 4724/4885KDM4E 3511/4885 |
| US-20190054118-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals | NR4A2, NR2C2, NR0B2 | ABCC8 2042/4885KCNJ11 4724/4885KDM4E 3511/4885 |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | NR4A2, NR2C2, NR0B2 | ABCC8 1987/4885KCNJ11 4734/4885KDM4E 3440/4885 |
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | NR4A2, NR2C2, NR2F2 | ABCC8 1939/4885KCNJ11 4762/4885KDM4E 3502/4885 |
| US-10472351-B2 | Small molecule agonists and antagonists of NR2F6 activity in animals | NR4A2, NR2C2, NR0B2 | ABCC8 2042/4885KCNJ11 4724/4885KDM4E 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.